A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329
NCT ID: NCT00934089
Last Updated: 2021-05-03
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
31 participants
INTERVENTIONAL
2010-01-31
2010-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
NCT00572455
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
NCT00441883
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
NCT02083289
A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.
NCT00638742
Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients
NCT00069706
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PF-04217329 + placebo
Active study drug + latanoprost vehicle
PF-04217329
Topical ocular solution, once-daily for 14 days
latanoprost vehicle
Topical ocular solution, once-daily for 14 days
PF-04217329 + latanoprost
Active study drug + latanoprost
PF-04217329
Topical ocular solution, once-daily for 14 days
latanoprost
Topical ocular solution, once-daily for 14 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PF-04217329
Topical ocular solution, once-daily for 14 days
latanoprost vehicle
Topical ocular solution, once-daily for 14 days
PF-04217329
Topical ocular solution, once-daily for 14 days
latanoprost
Topical ocular solution, once-daily for 14 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Intraocular Pressure (IOP) of at least 22 mmHg and not more than 30 mmHg in either eye at 8 AM after discontinuing previous glaucoma treatment
* Visual acuity correctable to 20/100 or better in each eye.
Exclusion Criteria
* Diagnosis of a clinically significant or progressive retinal disease (eg, diabetic retinopathy, macular degeneration) in either eye.
* Advanced glaucoma or a history of severe central visual field loss in either eye.
* History of ocular surgery or trauma in either eye within 6 months of the screening visit.
* History of ocular infection, ocular inflammation, or laser surgery in either eye within 3 months of the screening visit.
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
West Coast Clinical Trials, LLC
Cypress, California, United States
Glory Medical Group
Garden Grove, California, United States
East-West Eye Institute
Gardena, California, United States
Ophthalmology Corporation
Long Beach, California, United States
East-West Eye Institute
Los Angeles, California, United States
Los Angeles Eye Medical Group
Los Angeles, California, United States
Eye Research Foundation
Newport Beach, California, United States
Southern California Glaucoma Consultants
Pasadena, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A0191002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.